Table 3

Univariable analyses examining response, toxicities, PFS and OS in association with body composition measures (n=287)

ResponseOR95% CIP value
 SMI (sarcopenic vs non-sarcopenic)0.890.56 to 1.420.62
 SMD (high vs low)1.150.72 to 1.830.56
 SMG (high vs low)1.240.77 to 1.990.37
 TATI (medium vs low)1.160.66 to 2.050.61
 TATI (high vs low)0.790.44 to 1.400.43
 Sarcopenic obese (yes vs no)0.600.30 to 1.200.15
Toxicities OR 95% CI P value
 SMI (sarcopenic vs non-sarcopenic)0.900.56 to 1.440.67
 SMD (high vs low)0.780.49 to 1.250.30
 SMG (high vs low)0.840.52 to 1.350.47
 TATI (medium vs low)0.850.478 to 1.500.57
 TATI (high vs low)0.740.42 to 1.320.32
 Sarcopenic obese (yes vs no)0.620.31 to 1.230.17
PFS HR 95% CI P value
 SMI (sarcopenic vs non-sarcopenic)1.150.87 to 1.510.33
 SMD (high vs low)0.970.74 to 1.280.85
 SMG (high vs low)0.900.68 to 1.190.47
 TATI (medium vs low)0.820.58 to 1.160.26
 TATI (high vs low)1.110.80 to 1.550.51
 Sarcopenic obese (yes vs no) 1.47 1.02 to 2.12 0.037
OS HR 95% CI P value
 SMI (sarcopenic vs non-sarcopenic)1.280.93 to 1.770.135
 SMD (high vs low)0.760.55 to 1.040.09
 SMG (high vs low)0.780.57 to 1.080.14
 TATI (medium vs low)0.830.56 to 1.240.37
 TATI (high vs low)1.010.59 to 1.480.97
 Sarcopenic obese (yes vs no)1.340.88 to 2.050.17
  • P values ≦0.05 are displayed in bold.

  • OS, overall survival; PFS, progression-free survival; SMD, skeletal muscle density; SMG, skeletal muscle gauge; SMI, skeletal muscle index; TATI, total adipose tissue index.